KCAS, LLC

Founded in 1979 and based in Kansas, US, KCAS, LLC, doing business as KCAS – Bioanalytical & Biomarker Services is a bioanalytical contract research organization that provides analytical services for pharmaceutical, biotechnology, animal health, and medical device companies. In April 2021, Vitruvian Partners, acquired a majority stake in KCAS, LLC from Konza Valley Capital. As of 2021, the company employs more than 180 employees and its CEO is John Bucksath. KCAS provides comprehensive GLP-compliant bioanalytical and biomarker development testing services for the biotech, pharmaceutical, and animal health industries.

The company’s bioanalytical services range from early discovery support through registration to providing expertise in biological (large molecule) and synthetic (small molecule) drug candidates. The company’s services include ligand binding assays, LC-MS/MS, biomarkers service, and sample kits. Ligand binding assays are used in the biopharmaceutical sciences to quantitate proteins and anti-drug antibodies in biological fluids and tissues and LC-MS/MS is used to provide bioanalytical needs for drug discovery, preclinical, and clinical studies in biological fluids and tissues. Sample kits are the company's supplies and instructions services that are used in guiding clinical site personnel through the process of collecting various matrices/tissues as outlined within the protocol of user's trial and biomarkers service provides the measurements of analytes in biological fluids and tissues that are used to investigate the effect a drug has on a biological system The company plans to broaden its capabilities, expand its geographical reach starting with its construction of a 70,000 sq ft new facility in Kansas City, and scaling its business, and strategic acquisitions.